Search results: (10000)
News Reducing Overall Mortality by Combining Three Antihypertensives into a Single Pill
Treating hypertension to recommended target blood pressure values often requires a combination of three antihypertensives. By simply combining these three substances into a single pill, it is possible to increase treatment adherence, reduce overall mortality in hypertensive patients, and lower healthcare costs within one year. This is demonstrated by a freshly published Italian real-world study.
News Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab, omalizumab, and mepolizumab in patients with chronic rhinosinusitis and nasal polyps attempted to identify the most advantageous of the available biologics for this indication based on the ratio of benefits to risks.
News How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?
One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the relationship between uric acid levels and the incidence of cardiorenal events in type 2 diabetics with existing cardiovascular disease.
News Dabigatran vs. Warfarin: What and Why Do Patients Prefer?
The key to adherence to long-term anticoagulant therapy is primarily the satisfaction of patients with the set therapy. The RE-SONANCE study published in April 2021 compared patient satisfaction with anticoagulant treatment using the direct oral anticoagulant (DOAC) dabigatran versus vitamin K antagonists (VKAs). What were the findings?
News Quick Relief from Severe AD Symptoms – Dupilumab for Children Aged 6 Years and Older
Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.
News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis
What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC).
.
News With Prof. Pavel Žák about Current Trends and Future Perspectives in Bone Marrow Transplantation and the Role of Carmustine in this Context
Hematopoietic stem cell transplantation has an indispensable place in the treatment of hemato-oncological diseases. We discuss current trends in this area, the significance and benefits of carmustine, the choice between BEAM and TEAM regimens, and the future of bone marrow transplantation in the context of new technologies with the head of the 4th Department of Hematology of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, Prof. MUDr. Pavel Žák, Ph.D.
News Comparison of Enoxaparin and Unfractionated Heparin in Hospitalized Patients in Terms of Clinical and Cost Effectiveness
Thromboembolic disease represents one of the severe complications in hospitalized patients. Low molecular weight and unfractionated heparin are most commonly used during hospitalization as part of pharmacological thromboprophylaxis. An extensive study conducted in the United States evaluated the clinical and cost-effectiveness and safety of both therapy modalities in hospitalized patients at risk of thromboembolic disease.
News Dabigatran as Effective Prevention of VTE Recurrence Also in Patients with Thrombophilia
With increasing positive experience with direct oral anticoagulants, the question arises of how these drugs work in different groups of patients − for example, in those who have a congenital or acquired thrombophilic state.
News Alemtuzumab – Does Age Matter? Or Not?
The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?
News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice
Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
News How did alemtuzumab fare in real clinical practice?
A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?
News Diagnosing Myelodysplastic Syndrome According to MDS Europe
In 2021, the European Hematology Association (EHA) endorsed the recommendations of the MDS Europe group for the diagnosis of myelodysplastic syndrome (MDS). MDS-RIGHT is a large European project aimed at providing the right care to the right patients with MDS at the right time, based on clinically evidenced recommendations.
News Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency – Expert Consensus According to the DELPHI Methodology
Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies. Below, we briefly summarize recommendations concerning hemato-oncological patients with secondary immunodeficiency.
News How to Dose Beta-Blockers After Myocardial Infarction?
In patients after myocardial infarction (MI), there is a frequent administration of too low doses of beta-blockers (BB) and rare upward titration of their dose after discharge from the hospital. The SWEDEHEART study investigated to what extent the BB dose actually affects 5-year cardiovascular (CV) outcomes, and data from the American registry allowed a focus on mortality after MI depending on BB dosing.
News Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.
News Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice in the USA
A recently published study summarizes the characteristics of patients newly treated with tofacitinib for ulcerative colitis (UC), the impact of initiating tofacitinib on corticosteroid use, and adherence to this treatment in real-world practice based on a retrospective analysis of data from a large health database in the USA.
News Effect of Combination of Dorzolamide with Timolol for Wet Age-Related Macular Degeneration
In some eyes with wet age-related macular degeneration (AMD), exudation does not stop despite frequent intravitreal injections of vascular endothelial factor blockers (anti-VEGF). Adjuvant therapy that reduces edema may improve overall treatment outcomes concerning visual functions. A recently published multicenter randomized clinical study evaluated the effect of local therapy combining dorzolamide and timolol in patients with this issue.
News FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.
News Water Microjet as a Gentler Method of Debridement
Debridement is an integral part of chronic wound treatment. Currently, the most common method is mechanical debridement, which involves the use of sharp tools or abrasive materials to remove necrotic tissue. However, this method can be painful, imperfect, and associated with the risk of damaging healthy tissue. New and gentler methods are emerging, promising improved therapeutic outcomes, such as the use of a water microjet.
News Economic Burden and Loss of Quality of Life as a Consequence of Dry Eye Syndrome
Canadian authors evaluated the direct and indirect financial costs associated with dry eye syndrome (DED − dry eye disease) and the impact of this condition on the quality of life (QoL) of patients. The results were stratified according to the severity of the condition. The most significant was the loss of work productivity, highlighting the need for adequate solutions for DED.